Annexin Pharmaceuticals AB (publ) (STO:ANNX)
Sweden
· Delayed Price · Currency is SEK 14.50
+0.20 (1.40%)
At close: Mar 6, 2026
Annexin Pharmaceuticals AB Company Description
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases.
It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions.
Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden.
Annexin Pharmaceuticals AB (publ)
| Country | Sweden |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Anders Haegerstrand |
Contact Details
Address: Kammakargatan 48 Stockholm, 111 60 Sweden | |
| Website | annexinpharma.se |
Stock Details
| Ticker Symbol | ANNX |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0009664154 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anders Haegerstrand M.D., Ph.D. | Chief Executive Officer |
| Susanne Andersson | Chief Financial Officer |
| Susan Suchdev | Chief Operating Officer |
| Dr. Anna Frostegård M.D., Ph.D. | Chief Scientific and Medical Officer |
| Dr. Mario Fsadni L.L.M., M.Sc. | Therapeutic Area Head of Ophthalmology |